Nichols & Pratt Advisers LLP MA Increases Stock Holdings in Stryker Corporation $SYK

Nichols & Pratt Advisers LLP MA boosted its stake in Stryker Corporation (NYSE:SYK) by 3.9% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 53,166 shares of the medical technology company’s stock after acquiring an additional 2,020 shares during the quarter. Stryker accounts for about 1.1% of Nichols & Pratt Advisers LLP MA’s portfolio, making the stock its 28th biggest holding. Nichols & Pratt Advisers LLP MA’s holdings in Stryker were worth $17,470,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker during the fourth quarter worth about $26,000. Sankala Group LLC purchased a new position in Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC purchased a new position in Stryker in the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. acquired a new stake in Stryker in the 4th quarter worth about $27,000. Finally, DJE Kapital AG purchased a new stake in Stryker during the 4th quarter worth approximately $28,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on SYK. BMO Capital Markets initiated coverage on Stryker in a report on Wednesday. They set an “outperform” rating and a $369.00 target price for the company. Citigroup dropped their price target on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Wells Fargo & Company decreased their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Finally, Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research note on Friday, May 1st. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $393.91.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the sale, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 323,264 shares of company stock worth $100,659,489 in the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Down 0.8%

Shares of NYSE SYK opened at $327.17 on Thursday. The stock has a market cap of $125.42 billion, a P/E ratio of 37.87, a PEG ratio of 2.11 and a beta of 0.77. The business’s fifty day simple moving average is $309.71 and its 200-day simple moving average is $338.22. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is currently 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.